Condition
KSHV
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
6 treatments under study, led by Rituximab
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
Phase 1 (1)
Phase 2 (1)
Trial Status
Terminated1
Recruiting1
Clinical Trials (2)
Research Network
Common Treatments
- Rituximab1
- Standard Therapies1
- Sorafenib1
- Zidovudine1
- Liposomal Doxorubicin1
Active Sponsors
- National Cancer Institute (NCI)2
Top Investigators
National Cancer Institute (NCI)
Related Conditions
- Hhv82
- Kshv Inflammatory Cytokine Syndrome Kics1
- Kaposis Sarcoma1